IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3201
Positioning
Market Dominance
Manufacturing
Medical Equipment
$465M
David R. Bailey
OrthoPediatrics Corp. designs, develops, markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the. treatment of spinal deformity; and sports medicine and other products.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$KIDS ORTHOPEDIATRICS CORP | 42 | 51 | 41 | 29 | - | - | -10.7% | -7.6% | 73.1% | -16.0% | -16.4% | 16.0% | 0.0% | 28.0x | $465M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
ORTHOPEDIATRICS CORP (KIDS) receives a "Reduce" rating with a composite score of 42.4/100. It ranks #3201 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Fair valuation relative to peers
Average quality profile
Low volatility — smoother ride and historically better risk-adjusted returns
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for KIDS.
View All RatingsROIC -9.0% vs WACC 8.2% (spread -17.2%)
GM 73% vs sector 44%, OM -16% vs sector 3%
Capital turnover 0.74x, R&D intensity 3.9%
Rev growth 16%, 9yr history
Interest coverage -5.2x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate ORTHOPEDIATRICS CORP (KIDS) as a Reduce with a composite score of 42.4/100 at a current price of $16.09. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential.
ORTHOPEDIATRICS CORP holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 42.4/100 places it at rank #3201 in our full universe.
No Moat
Medium
Poor
Fair Value
Gross margins of 73% signal strong pricing power.
Stable competitive position in a defensive sector.
Weak momentum suggests persistent institutional selling pressure.
Vulnerability to macroeconomic shocks and interest rate volatility.
ORTHOPEDIATRICS CORP represents a reduce based on multi-factor quantitative performance.
ORTHOPEDIATRICS CORP receives a Reduce rating from our analysis, with a composite score of 42.4/100 and 2 out of 5 stars, ranking #3201 out of 7,333 stocks. KIDS's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
With a quality score of 51/100, KIDS shows adequate but unremarkable business quality. The company reports a return on equity of -10.7% (sector avg: -1.9%), gross margins of 73.1% (sector avg: 44.1%), net margins of -16.4% (sector avg: 1.0%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
With a value score of 41/100, KIDS appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 1.22x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
ORTHOPEDIATRICS CORP's investment score of 36/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 16.0% vs. a sector average of 6.7% and a return on assets of -7.6% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
ORTHOPEDIATRICS CORP is experiencing notably weak momentum with a score of just 29/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at 16.0% year-over-year, while a beta of 1.03 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
KIDS shows good financial stability with a score of 71/100. Key stability metrics include a beta of 1.03 and a debt-to-equity ratio of 28.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
ORTHOPEDIATRICS CORP's short interest score of 35/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 28.00x), small-cap liquidity risk. At $465M (small-cap), KIDS carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
ORTHOPEDIATRICS CORP is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3201 of 7,333 overall (56th percentile). Key comparisons include ROE of -10.7% trailing the -1.9% sector median and operating margins of -16.0% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While KIDS currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (29) would have the largest impact on the composite score.
ROE 465% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 66% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 737% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
WARSAW, Ind., Feb. 12, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. OrthoPediatrics will host a conference call on Thursday, February 26, 2026 at 4:30 p.m. ET to discuss the results. Investors inte
Bruker Corporation announced the acquisition of Dynamic Biosensors GmbH, a company known for its development in biosensors. The acquisition is expected to strengthen Bruker's position in the pharma and biotech industries by leveraging its leading high-throughput Surface Plasmon Resonance portfolio and Dynamic Biosensors' unique instruments.
OrthoPediatrics Corp. (KIDS) has launched its Enabling Technologies division, which will leverage the company's core mission of addressing unmet pediatric needs in orthopedics. The new division is expected to differentiate KIDS' core business, generate sustainable revenue growth, and gain access to new markets and specialties beyond orthopedics.
Other successful elites like Warren Buffett, Mitzi Perdue, and Mark Cuban live under their means in quaint houses and apartment rentals.